Skip to main content
Fact Sheet
Health

Smoking and Eye Disease

ASH
Feb 2019
Download PDF

Introduction

Tobacco smoke is a hazardous mixture of over 5,000 chemicals, many of which are toxic and potentially damaging to the eyes.1 This fact sheet focuses on some of the major eye conditions that can be caused or exacerbated by smoking: Age-related Macular Degeneration, Cataracts, Diabetic retinopathy, Thyroid eye disease and Optic neuropathy.

Age-related Macular Degeneration (AMD)

Age related macular degeneration (AMD) is an umbrella term for a variety of degenerative conditions affecting the macula, the small central area of the retina at the back of the eye which is responsible for clear, central vision.2 When the macula is damaged, vision becomes blurred, distorted and dark in the centre (this is called a scotoma). Although peripheral vision is not affected by AMD, loss of central vision means that everyday activities such as reading, driving and watching television become difficult or impossible.

There are several potential biological mechanisms linking smoking and AMD. In short: cigarette smoke is likely to have toxic effects on the retina.3 Smoking causes oxidative stress, damages the retina and reduces blood flow in the eye tissue. 4 This leads to oxygen deprivation in the macula which can result in tissue death.5

Smoking is the major preventable risk factor for all types of AMD.6 A 2005 British study concluded that at the time, approximately 28,000 cases of AMD in older people in the United Kingdom could be attributable to smoking.7 Smoking at least doubles the risk of developing AMD, which tends to develop earlier in smokers, although those that have quit smoking for 20 years or more have roughly the same risk of developing AMD as non-smokers.7 8 There is a dose-response relationship that leaves heavier smokers at higher risk of developing AMD.9 The risk of developing AMD is also greater for smokers with a genetic predisposition to the condition.10

Cataracts

A cataract is a clouding in the lens of the eye that causes blurred vision and, if left untreated, can lead to vision loss. Cataracts often develop as part of the normal ageing process. In England and Wales, it is estimated that around 2.5 million people aged 65+ have some degree of visual impairment caused by cataracts.11 In the UK, over 400,000 cataract operations are performed every year.12

Smoking is a major risk factor in the development of cataracts.13 Smoking leads to around a 3-fold increase in the risk of cataract development.14 A smoker’s risk of developing cataracts increases with the amount smoked and cataracts are more severe in heavy smokers.15

Although the exact mechanism by which smoking causes cataracts to develop is not fully understood, the destruction of antioxidant nutrients by cigarette smoke is one potential hypothesis, as antioxidants may help maintain lens transparency.16 Cigarette smoking may also break down other micronutrients critical to healthy eye tissues.17

Diabetic Retinopathy

Diabetic retinopathy is an eye complication associated with diabetes in which the blood vessels that supply the retina are damaged by high blood sugar levels. When these blood vessels become damaged, they can leak fluid or blood and grow scar tissue which can distort the images the retina sends to the brain. This can eventually lead to blindness.18 Around 150,000 patients suffer from diabetic retinopathy in the UK.19

Smoking is a significant risk factor for developing diabetic retinopathy in type 1 and type 2 diabetes.20 21 Stopping smoking, along with improved metabolic control amongst type 1 diabetics is protective against retinopathy.

The mechanisms in which smoking can lead to diabetic retinopathy are unclear. Smoking can also cause tissue hypoxia in retinal vessels which might contribute to the development of the condition.22

Smoking also increases blood pressure and raises blood sugar levels in diabetics, therefore making it more difficult to control the diabetes which can cause retinopathy in the first place. For further information about smoking and diabetes see ASH Fact Sheet: Smoking and Diabetes.

Thyroid Eye Disease

Thyroid eye disease (TED), is an autoimmune disease in which the eye muscles and fatty tissue behind the eye become inflamed. This can cause the eyes to be pushed forward (‘staring’ or ‘bulging’ eyes) and the eyes and eyelids to become swollen and red.23 TED is mainly associated with Graves’ disease, where the thyroid gland becomes overactive and releases too much thyroid hormone. At least 80% of TED is associated with Graves’ disease.24 However, TED can also occur in people with normally functioning thyroids.25 Along with protrusion of the eyes, double vision and loss of vision, sometimes causing blindness, can occur. TED is a rare condition with an incidence of 2.9 to 16 cases per 100,000 people, per year.26

There is strong evidence of an association between smoking and the development of thyroid eye disease, which is related to the number of cigarettes smoked per day27. People with Graves’ disease who smoke have a four-fold increased risk of developing the condition, when compared to non-smokers.28 The reason for smokers’ increased risk of developing Graves disease is not fully understood but it could be partly due to the smoking-induced impairment of the immune system.29 Other theories for biological mechanisms linking smoking to TED have also been proposed: smoking may have a direct irritant action on the eye, causing inflammatory changes; smoking might cause a stimulation of the autoimmune process in smokers and smoking might influence cytokine secretion in the eye.30

Optic Neuropathy

Optic neuropathy is damage to the optic nerve (which transmits visual information from the retina to the brain) from any cause. Anterior ischaemic optic neuropathy (AION) is a type of optic neuropathy which results in sudden, painless loss of vision, often leading to permanent blindness.31 Smoking might also play a role in the development of anterior ischaemic optic neuropathy.32 This is because smoking is a risk factor for the development of atherosclerosis, where plaques form within arteries, and this could lead to the optic nerve not receiving enough blood.33

Leber’s hereditary optic neuropathy (LHON) is a mitochondrially inherited disease where the retinal ganglion cells are degenerated, leading to loss of central vision.34 Evidence suggests that smoking increases the risk of visual failure in people genetically predisposed to developing LHON.35 The increased susceptibility of smoking LHON carriers to optical neuropathy could be due to the way cigarette smoke affects mitochondrial DNA and its effects on oxidative phosphorylation.

Passive Smoking and Eye Disease

Non-smokers often complain of eye irritation when exposed to cigarette smoke. However, there is relatively scarce quantitative data in the literature on the direct effects of environmental cigarette smoke (otherwise known as ‘second-hand smoke (SHS)’) on diseases of the eye. A 2008 review article found seven studies which had looked at the possible relationship between SHS and eye-disease and found no conclusive relationships between SHS and eye conditions in any of the studies they analysed.36

Pregnant Smokers and Eye Disease

Maternal smoking has been found to increase the risk of a number of eye defects in unborn children including: astigmatism (misshapen eyes), anophthalmia (absence of eye), microphthalmia (abnormally small eyes), strabismus (crossed eyes), esotropia (both eyes turned inwards), exotropia (eyes turned outwards) and optic nerve hypoplasia (underdeveloped or absent optic nerve).37 38 39

Public Awareness & Educational Campaigns

A 2013 survey carried out in the UK found that just 15% of smokers were concerned about the impact smoking has on their eye health.40 An earlier international comparison found that a low proportion of smokers in Canada (13.0%), the United States (9.5%), and the United Kingdom (9.7%) believed that smoking can cause blindness. In contrast, 47.2% of Australian smokers believed that smoking causes blindness. 41 42

In the UK, there is also a lack of knowledge about eye diseases in general, for instance a 2012 survey found that 29% of people in Great Britain said they had never heard of AMD, a major eye-disease.43

British youth are similarly unclear about the link between smoking and eye-disease. A 2006 survey of UK teenagers found they were far more likely to believe that smoking ‘probably’ or ‘definitely’ causes lung cancer (81%), compared with heart disease (27%), stroke (15%) and that only 5% identified smoking as a risk for blindness.44 Youth in other developed countries such as Canada and the US are similarly unaware of the impact of smoking on ocular health.45

Mass media campaigns in Australia and New Zealand have been very successful in raising awareness about the risk of eye diseases associated with smoking. As early as the year 2000, the Australian National Quit campaign ran an advertisement as part of a series entitled, “Every cigarette is doing you damage,” which explicitly addressed AMD.46 In March 2007, Australia became the first country to include a pictorial warning label on cigarette packages with the message that smoking causes blindness.

An analysis of Australia’s National Tobacco Campaign showed that the advertisement conveying information about the association between smoking and blindness was more efficient in generating quit-line calls than the “tar” advertisement, which emphasised the effects of tar on a smoker’s lungs.47

On October 1, 2008, the UK introduced picture warnings on cigarette packets, but these warnings originally did not include information about smoking and blindness.48 In March of 2012, the European Commission formally adopted a new warning: “smoking increases the risk of blindness,” which was to begin appearing on tobacco packs within two years.49 The number of countries which have mandated pack warnings related to blindness is slowly increasing, currently it includes: Canada (2006), New Zealand (2008), Iran (2009), Colombia (2011), Jamaica (2013), Panama (2014) and Suriname (2014).50

Professional Advice

The advice of the 2010 US Surgeon General’s Report on smoking is that eye-care professionals should counsel patients to quit smoking.51 Including training for smoking cessation counselling in ophthalmology curriculums could also help to promote smoking cessation. 43

Evidence suggests that more needs to be done in the UK to get optometrists to persuade smokers to quit. As it stands, most eye care providers assess their patients’ smoking status and discuss the risks of smoking on the eyes, however, not many will actively promote smoking cessation options with their patients. In 2012, a survey found that only one in three optometrists in the United Kingdom regularly assessed patients’ smoking status and advised on smoking cessation.52 A 2015 survey of UK optometry training found that the majority of undergraduate optometry schools in the UK dedicate extremely limited hours (0-3) to smoking cessation, in their entire undergraduate courses.53

  • [1]

    Talhout R, Schulz T, Florek E, Van Benthem J, Wester P, Opperhuizen A. Hazardous compounds in tobacco smoke. International journal of environmental research and public health. 2011 23;8(2):613-28.

  • [2]

    National Eye Institute Facts About Age-Related Macular Degeneration, 2015

  • [3]

    Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye. 2005 Sep;19(9):935.

  • [4]

    American Council on Science and Health. Cigarettes: What the warning label doesn’t tell you—Information tobacco companies don’t want teens to know about the dangers of smoking. New York: American Council on Science and Health; 2003 p. 98-130.

  • [5]

    Khan JC, Thurlby DA, Shahid H, Clayton DG, Yates JR, Bradley M, Moore AT, Bird AC. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. British
    Journal of Ophthalmology. 2006 Jan 1;90(1):75-80.

  • [6]

    Evans J. 28,000 cases of age related macular degeneration causing visual loss in people aged 75 years and above in the United Kingdom may be attributable to smoking. British Journal of Ophthalmology. 2005;89(5):550-553.

  • [7]

    Yu SS, Tang X, Ho YS, Chang RC, Chiu K. Links between the brain and retina: The effects of cigarette smoking-induced age-related changes in
    Alzheimer’s disease and macular degeneration. Frontiers in neurology. 2016 Jul 27;7:119.

  • [8]

    Armstrong RA, Mousavi M. Overview of risk factors for age-related macular degeneration (AMD). Journal of stem cells. 2015 Jul 1;10(3):171.

  • [9]

    Seddon JM. Genetic and environmental underpinnings to age-related ocular diseases. Investigative Ophthalmology & Visual Science. 2013 Dec 13;54(14):ORSF28-30.

  • [10]

    Specsavers Cataracts.

  • [11]

    The Royal College of Ophthalmologists A short guide to a career in ophthalmology in the UK, 2016.

  • [12]

    Hodge WG, Whitcher JP, Satariano W. Risk factors for age-related cataracts. Epidemiologic reviews. 1995;17(2):336-46.

  • [13]

    Kelly S, Thornton J, Edwards R, Sahu A, Harrison R. Smoking and cataract: review of causal association. Journal of Cataract & Refractive
    Surgery. 2005;31(12):2395-2404.

  • [14]

    Robman L, Taylor H. External factors in the development of cataract. Eye. 2005 Oct;19(10):1074-1082.

  • [15]

    Robman L, Taylor H. External factors in the development of cataract. Eye. 2005 Oct;19(10):1074-1082.

  • [16]

    Sulochana KN, Punitham R, Ramakrishnan S. Effect of cigarette smoking on cataract: Antioxidant enzymes and constituent minerals in the lens
    and blood of humans. Indian journal of pharmacology. 2002 Nov 1;34(6):428-31.

  • [17]

    Alberg AJ. The influence of cigarette smoking on circulating concentrations of antioxidant micronutrients. Toxicology. 2002 Nov 15;180(2):121-37.

  • [18]

    NHS. Overview, Diabetic retinopathy. NHS. 2016.

  • [19]

    Mathur R, Douglas I, Bhaskaran K, Smeeth L. Diabetic eye disease: A UK Incidence and Prevalence Study. 2017

  • [20]

    Hammes HP, Kerner W, Hofer S, Kordonouri O, Raile K, Holl RW. Diabetic retinopathy in type 1 diabetes-a contemporary analysis of 8,784 patients. Diabetologia. 2011 Aug;54(8):1977-1984.

  • [21]

    Zhong ZL, Han M, Chen S. Risk factors associated with retinal neovascularization of diabetic retinopathy in type 2 diabetes mellitus. International Journal of Ophthalmology. 2011;4(2):182-185.

  • [22]

    Kifley A, Liew G, Wang JJ, Kaushik S, Smith W, Wong TY, Mitchell P. Long-term effects of smoking on retinal microvascular caliber. American journal of epidemiology. 2007 Oct 12;166(11):1288-97.

  • [23]

    British Thyroid Foundation. Thyroid Eye Disease. 2015.

  • [24]

    Cockerham KP, Chan SS. Thyroid eye disease. Neurologic clinics. 2010 Aug 1;28(3):729-55.

  • [25]

    Bahn RS. Graves’ ophthalmopathy. New England Journal of Medicine. 2010 Feb 25;362(8):726-38.

  • [26]

    Perros P, Neoh C, Dickinson J. Thyroid eye disease. BMJ: British Medical Journal (Online). 2009 Mar 6;338.

  • [27]

    Wiersinga WM. Smoking and thyroid. Clin Endocrinol (Oxf). 2013;79:145-51

  • [28]

    Hegedüs L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves’ ophthalmopathy. Journal of endocrinological investigation. 2004 Mar 1;27(3):265-71.

  • [29]

    Stämpfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nature Reviews Immunology. 2009 May;9(5):377.

  • [30]

    Thornton J, Kelly SP, Harrison RA, Edwards R. Cigarette smoking and thyroid eye disease: a systematic review. Eye. 2007 Sep;21(9):1135.

  • [31]

    Medscape. Anterior Ischemic Optic Neuropathy (AION), 2017.

  • [32]

    Gordon JS, Andrews JA, Lichtenstein E, Severson HH, Akers L, Williams C. Ophthalmologists’ and optometrists’ attitudes and behaviours regarding tobacco cessation intervention. Tobacco Control. 2002 Mar 1;11(1):84-5.

  • [33]

    Frostegård J. Immunity, atherosclerosis and cardiovascular disease. BMC medicine. 2013 Dec;11(1):117.

  • [34]

    Man PY, Turnbull DM, Chinnery PF. Leber hereditary optic neuropathy. Journal of medical genetics. 2002 Mar 1;39(3):162-9.

  • [35]

    Kirkman MA, Yu-Wai-Man P, Korsten A, Leonhardt M, Dimitriadis K, De Coo IF, Klopstock T, Chinnery PF. Gene–environment interactions in Leber hereditary optic neuropathy. Brain. 2009 Jun 12;132(9):2317-26.

  • [36]

    Lois N, Abdelkader E, Reglitz K, Garden C, Ayres J. Environmental tobacco smoke (ETS) exposure and eye disease. British Journal of Ophthalmology. 2008 Jul 25.

  • [37]

    Hackshaw A, Rodeck C, Boniface S. Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls. Human reproduction update. 2011 Sep 1;17(5):589-604.

  • [38]

    McKean-Cowdin R, Varma R, Cotter SA, Tarczy-Hornoch K, Borchert MS, Lin JH, Wen G, Azen SP, Torres M, Tielsch JM, Friedman DS. Risk factors for astigmatism in preschool children: the multi-ethnic pediatric eye disease and Baltimore pediatric eye disease studies. Ophthalmology. 2011 Oct 1;118(10):1974-81.

  • [39]

    Pueyo V, Güerri N, Oros D, Valle S, Tuquet H, González I, Ferrer C, Pablo LE. Effects of smoking during pregnancy on the optic nerve neurodevelopment. Early human development. 2011 May 1;87(5):331-4.

  • [40]

    Optician, Most smokers unaware of eye health risk. 2018.

  • [41]

    Kennedy RD, Spafford MM, Parkinson CM, Fong GT. Knowledge about the relationship between smoking and blindness in Canada, the United States, the United Kingdom, and Australia: results from the International Tobacco Control Four-Country Project. Optometry-Journal of the American Optometric Association. 2011 May 1;82(5):310-7.

  • [42]

    Kennedy RD, Spafford MM, Behm I, Hammond D, Fong GT, Borland R. Positive impact of A ustralian ‘blindness’ tobacco warning labels: findings from the ITC four country survey. Clinical and Experimental Optometry. 2012 Nov;95(6):590-8.

  • [43]

    The College of Optometrists, Britain’s Eye Health in Focus: A snapshot of consumer attitudes and behaviour towards eye health. 2013.

  • [44]

    Moradi P, Thornton J, Edwards R, Harrison RA, Washington S, Kelly SP. Teenagers’ perceptions of blindness related to smoking-novel message
    to a vulnerable group. British journal of ophthalmology. 2007 Feb 6.

  • [45]

    Brûlé J, Tousignant B, Marcotte S, Moreau MC. Smoking and the eye: what Québec teenagers know and fear. Clinical and Experimental Optometry. 2018 Jan;101(1):73-6.

  • [46]

    Hill D, Carroll T. Australia’s national tobacco campaign. Tobacco Control. 2003 Sep 1;12(suppl 2):ii9-14.

  • [47]

    Carroll T, Rock B. Generating Quitline calls during Australia’s National Tobacco Campaign: effects of television advertisement execution and programme placement. Tobacco Control. 2003 Sep 1;12(suppl 2):ii40-4.

  • [48]

    Action on Smoking and Health, Press release on 1 October 2008: Implementation of picture warnings on tobacco products. 2008

  • [49]

    European Commission, Commission Directive of 2012/9/EU of 7 March 2012. 2012

  • [50]

    Tobacco Labelling Resource Centre, Health Effects – Eye. 2013

  • [51]

    Office of the Surgeon General. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A
    Report of the Surgeon General. Rockville: U.S. Department of Health and Human Services, 2014.

  • [52]

    Lawrenson JG, Evans JR. Advice about diet and smoking for people with or at risk of age-related macular degeneration: a cross-sectional survey
    of eye care professionals in the UK. BMC Public Health. 2013 Dec;13(1):564.

  • [53]

    Lorencatto F, Harper AM, Francis JJ, Lawrenson JG. A survey of UK optometry trainees’ smoking cessation training. Ophthalmic and Physiological Optics. 2016 Jul;36(4):494-502.